PMID- 35101086
OWN - NLM
STAT- MEDLINE
DCOM- 20220202
LR  - 20220204
IS  - 1745-6215 (Electronic)
IS  - 1745-6215 (Linking)
VI  - 23
IP  - 1
DP  - 2022 Jan 31
TI  - Effect of acupuncture therapy combined with fluticasone propionate in the 
      treatment of persistent allergic rhinitis: study protocol for a randomized 
      controlled trial.
PG  - 94
LID - 10.1186/s13063-022-06020-6 [doi]
LID - 94
AB  - BACKGROUND: Allergic rhinitis (AR) is an immunoglobulin E (IgE)-mediated 
      inflammatory response. Persistent allergic rhinitis (PAR) is a subtype of AR, but 
      the treatment of PAR is still a problem. Acupuncture is used as an alternative 
      therapy for AR in clinical practice. The aim of this study is to evaluate the 
      effectiveness of acupuncture therapy combined with fluticasone propionate nasal 
      spray in comparison to fluticasone propionate nasal spray alone in the relief of 
      symptoms for PAR. METHODS: This study is a multicenter, single-blind, randomized 
      controlled trial. A total of 260 eligible patients will be randomly assigned into 
      the treatment group or the control group. The treatment group will receive the 
      nasal fluticasone propionate combined with acupuncture, and the control group 
      will receive fluticasone propionate nasal spray alone for 6 weeks. The primary 
      outcome is the change in the Reflective Total Nasal Symptom Score (rTNSS) from 
      baseline to the end of treatment, and the Total Non Nasal Symptom Score (TNNSS), 
      reflective total ocular symptom score (rTOSS), Rhinitis Quality of Life 
      Questionnaire (RQLQ), use of antiallergic drugs, and the Rhinitis Control 
      Assessment Test (RCAT) are used as secondary outcomes. The participants will be 
      followed up for another 24 weeks after treatment. DISCUSSION: This clinical trial 
      will be able to provide high level evidence on the acupuncture therapy combined 
      with fluticasone propionate nasal spray in the treatment of PAR. TRIAL 
      REGISTRATION: ISRCTN Registry, ID: ISRCTN44040506 . Registered on 22 July 2020.
CI  - (c) 2022. The Author(s).
FAU - Fan, Qi
AU  - Fan Q
AD  - Institute of Acupuncture and Moxibustion, China Academy of Chinese Medical 
      Sciences, Beijing, 100700, China.
AD  - Luohu District Hospital of Traditional Chinese Medicine, ShenZhen, 518004, China.
FAU - Feng, Yixuan
AU  - Feng Y
AD  - Institute of Acupuncture and Moxibustion, China Academy of Chinese Medical 
      Sciences, Beijing, 100700, China.
FAU - Hou, Yan
AU  - Hou Y
AD  - Peking University, Beijing, 100871, China.
FAU - Wu, Feihu
AU  - Wu F
AD  - The First Affiliated Hospital of Anhui University of Chinese Medicine, HeFei, 
      230031, China.
FAU - Zhang, Wei
AU  - Zhang W
AD  - The First Affiliated Hospital of Hunan University of Traditional Chinese 
      Medicine, Changsha, 410000, China.
FAU - Nie, Wenbin
AU  - Nie W
AD  - Institute of Acupuncture and Moxibustion, China Academy of Chinese Medical 
      Sciences, Beijing, 100700, China.
FAU - Li, Bin
AU  - Li B
AD  - Beijing Hospital of Traditional Chinese Medicine, Capital Medical University, 
      Beijing, 100010, China.
FAU - Zhou, Zhongyu
AU  - Zhou Z
AD  - HuBei Provincial Hospital of Traditional Chinese Medicine, Wuhan, 430061, China.
FAU - Fu, Wenbin
AU  - Fu W
AD  - Guangdong Provincial Hospital of Chinese Medicine, Guangzhou, 510120, China.
FAU - Shi, Lei
AU  - Shi L
AD  - First Teaching Hospital of Tianjin University of Traditional Chinese Medicine, 
      Tianjin, 300381, China.
FAU - Sun, Zhongren
AU  - Sun Z
AD  - The Second Hospital of HeiLongjiang University of Chinese Medicine, Harbin, 
      150009, China.
FAU - Zhao, Hong
AU  - Zhao H
AUID- ORCID: 0000-0001-8211-9483
AD  - Luohu District Hospital of Traditional Chinese Medicine, ShenZhen, 518004, China.
LA  - eng
GR  - ZZ13-024-9/China Academy of Chinese Medical Sciences/
GR  - TCM-Project BEBPC-TC(NO.2019XZZX-ZJ/National administration of Traditional 
      Chinese Project/
PT  - Clinical Trial Protocol
PT  - Journal Article
DEP - 20220131
PL  - England
TA  - Trials
JT  - Trials
JID - 101263253
RN  - 0 (Androstadienes)
RN  - CUT2W21N7U (Fluticasone)
SB  - IM
MH  - *Acupuncture Therapy/adverse effects
MH  - Androstadienes/adverse effects
MH  - Fluticasone/adverse effects
MH  - Humans
MH  - Multicenter Studies as Topic
MH  - Quality of Life
MH  - Randomized Controlled Trials as Topic
MH  - *Rhinitis, Allergic/diagnosis/therapy
MH  - Single-Blind Method
MH  - Treatment Outcome
PMC - PMC8802421
OTO - NOTNLM
OT  - Acupuncture therapy
OT  - Persistent allergic rhinitis
OT  - Randomized controlled trial
OT  - Study protocol
COIS- The authors declare that they have no competing interests.
EDAT- 2022/02/02 06:00
MHDA- 2022/02/03 06:00
PMCR- 2022/01/31
CRDT- 2022/02/01 05:44
PHST- 2021/05/15 00:00 [received]
PHST- 2022/01/11 00:00 [accepted]
PHST- 2022/02/01 05:44 [entrez]
PHST- 2022/02/02 06:00 [pubmed]
PHST- 2022/02/03 06:00 [medline]
PHST- 2022/01/31 00:00 [pmc-release]
AID - 10.1186/s13063-022-06020-6 [pii]
AID - 6020 [pii]
AID - 10.1186/s13063-022-06020-6 [doi]
PST - epublish
SO  - Trials. 2022 Jan 31;23(1):94. doi: 10.1186/s13063-022-06020-6.